Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION

v3.23.2
STOCK-BASED COMPENSATION
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATIONIn 2015, the Company’s Board of Directors approved the HeartBeam, Inc. 2015 Equity Incentive Plan ("2015 Plan"), to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to employees, directors, and consultants, and to promote the success of the Company’s business. The 2015 Plan provides for the grant of stock options and RSU’s to purchase common stock of which 1,636,362 were authorized by the board of which
1,083,749 are outstanding. The 2015 Plan was terminated upon shareholder approval of the 2022 Equity Incentive Plan (“2022 Equity Plan”) whereby no new awards can be issued under the 2015 Plan.

The Company’s shareholders approved the 2022 Equity Plan at the annual meeting of stockholders held on June 15, 2022, pursuant to which 1,900,000 shares of common stock were authorized for issuance. Under the 2022 Equity Plan, the number of shares available for issuance will be increased on the first day of each fiscal year beginning with the 2023 fiscal year, in an amount equal to the lesser of 3,800,000 shares, five percent (5%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, and a lesser number of shares determined by the administrator. On January 1, 2023 400,487 shares, equivalent to five percent (5%) of common stock outstanding were added to the shares available for issuance under the 2022 Equity Plan.

The 2022 Equity Plan includes a provision to add-back any cancelled options from the 2015 Plan up to 1,372,816 shares. As of June 30, 2023, there are 160,689 shares from the 2015 Plan that are included in the 222,885 shares available for issuance under the 2022 Equity Plan.
The Company received proceeds of $0.1 million from the exercise of stock options during the quarter ended June 30, 2023 and a de minimis amount during the quarter ended June 30, 2022.

STOCK OPTIONS
The following is a summary of stock option activity during the six months ended June 30, 2023:
Number of
options
outstanding
Weighted
average
exercise
price
Average
remaining
contractual life
(in years)
Aggregate
intrinsic value
(in thousands)
Outstanding – December 31, 2022
2,196,798  $ 1.76  8.7 $ 6,770 
Options granted
1,115,800  2.62  —  — 
Options exercised
(88,026) 1.17  —  — 
Options cancelled (195,834) 1.70  —  — 
Outstanding – June 30, 2023
3,028,738  2.10  8.7 2,040 
Exercisable – June 30, 2023
1,052,605  $ 1.64  7.6 $ 1,177 
The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. For the six months ended June 30, 2023 and 2022, the assumptions used in the Black-Scholes option pricing model, which was used to estimate the grant date fair value per option, were as follows:
Six months ended June 30,
2023 2022
Weighted-average Black-Scholes option pricing model assumptions:
Volatility
110.23% - 111.73%
107.25% - 110.98%
Expected term (in years)
5.71 - 6.07
5.73 - 5.80
Risk-free rate
3.54% - 3.80%
1.47% - 2.85%
Expected dividend yield $ —  $ — 
Weighted average grant date fair value per share
$1.73 - $3.38
$1.08 - $1.75
RESTRICTED STOCK UNITS

The following is a summary of RSU’s awards activity:
Six months ended June 30, 2023
Numbers of Shares Weighted Average Grant Date Fair value
Non-Vested at beginning of period 253,970  $ 1.47 
Shares granted 5,000  2.24 
Shares vested (12,500) 2.82 
Non-vested 246,470  $ 1.44 

STOCK BASED COMPENSATION

The following is a summary of stock-based compensation expense:
Three months ended June 30, Six months ended June 30,
2023 2022 2023 2022
General and administrative
Stock options 507,200  175,900  707,200  296,800 
RSU’s 116,400  23,100  217,400  35,000 
Total general and administrative 623,600  199,000  924,600  331,800 
R&D
Stock options 78,800  64,800  170,800  90,900 
Total $ 702,400  $ 263,800  $ 1,095,400  $ 422,700 

As of June 30, 2023, total compensation cost not yet recognized related to unvested stock options and unvested RSUs was approximately $3.5 million and $0.01 million, respectively, which is expected to be recognized over a weighted-average period of 2.23 years and 0.03 years, respectively.